News & Updates

Use of oral antibiotics in the treatment of osteomyelitis, bacteraemia, and infective endocarditis results in shorter hospital stay, has a better safety profile, and appears to be similarly effective when compared to intravenous (IV)-only therapy, a recent study has shown.

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.

Treatment with intravenous brivaracetam is well tolerated in children with epilepsy, with a safety profile consistent with that known of the oral formulation, according to the results of a phase II study. There has been no pharmacokinetic difference observed when administered as bolus or a 15-minute infusion.

Gout patients have about sixfold greater odds of experiencing a flare in the first few months after COVID-19 vaccination, but colchicine appears to keep these gout attacks at bay, as shown in a study from China.

The COVID-19 pandemic has worsened the adherence to ocular hypotensive medication among patients with primary open-angle glaucoma (POAG), according to a study. Such reduction is potentially driven by lower psychometric measures of resilience and more confrontational coping strategies.

Receipt of a booster dose of the COVID-19 vaccine reduces the risk of breakthrough COVID-19 infections* compared to full vaccination only, particularly among individuals without immunosuppressed/compromised conditions (ISC), according to a US study presented at CROI 2022.

A knowledge gap exists on the effects of direct oral anticoagulants (DOACs), but most nonvalvular atrial fibrillation (NVAF) patients with liver disease still begin treatment with these medications, particularly apixaban and rivaroxaban, a study has found.

Use of antihypertensive medications is associated with the incidence of psoriasis, reports a study. Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), and thiazide diuretics result in an increased risk of psoriasis.